Brief: Elicera Therapeutics: Final Data From Phase I/IIa Trial

Elicera Therapeutics AB

09/01/2026 13:10

Jan 9 (Reuters) - Elicera Therapeutics AB ELIC.ST:

ELICERA THERAPEUTICS ANNOUNCES FINAL DATA FROM ITS PHASE I/IIA TRIAL DEMONSTRATING A FAVORABLE SAFETY PROFILE AND PROMISING EFFICACY SIGNALS OF ONCOLYTIC VIRUS ELC-100 IN NEUROENDOCRINE TUMORS

STUDY DEMONSTRATES THAT ELC-100, WAS GENERALLY WELL-TOLERATED WITH NO DOSE-LIMITING TOXICITIES OBSERVED.

TRIAL ALSO REVEALED PROMISING EFFICACY SIGNALS

SAFETY PROFILE WAS CONSISTENT WITH EXPECTED MECHANISM OF ACTION OF AN ONCOLYTIC VIRU

SAFETY PROFILE WAS CONSISTENT WITH EXPECTED MECHANISM OF ACTION OF AN ONCOLYTIC VIRUS

Source text: ID:nWkr9qGW81

Further company coverage: ELIC.ST

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))